Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
AI-09 in glabellar lines
NCT07321834Phase 2Active, not recruiting
- Sponsor
- Eirion Therapeutics
- Start
- Dec 2025
- Primary completion
- Feb 2026
- Modality
- Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
A Phase 2 trial of AI-09 in glabellar lines, sponsored by Eirion Therapeutics. Started Dec 2025; status: active, not recruiting.
02
Drugs
AI-09
03
Conditions
glabellar lines
Beyond the preview
Go deeper on NCT07321834.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07321834.